Anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Drug Profile

Anti-CD19 chimeric antigen receptor T cell therapy - Innovative Cellular Therapeutics

Alternative Names: dPD-1 hCD19CART

Latest Information Update: 16 May 2017

Price : $50

At a glance

  • Originator Innovative Cellular Therapeutics
  • Developer Innovative Cellular Therapeutics; Zhejiang University
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action CD19 antigen modulators; Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma
  • Clinical Phase Unknown Leukaemia

Most Recent Events

  • 05 May 2017 Innovative Celluar Therapeutics initiates a phase I/II trial for B-cell lymphoma in China (ChiCTR-OIC-17011310)
  • 05 Apr 2017 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (IV) (NCT03118180)
  • 06 May 2016 Efficacy data from a Clinical trial in Leukaemia and B-cell lymphoma released by Innovative Cellular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top